Isomorphic Labs is taking AI drug discovery from theory to reality. The DeepMind spinoff announced at WIRED Health in London that they've developed a pipeline of new medicines ready for human trials.
This is a big deal because it shows AI can do more than just predict protein structures. Isomorphic is using those predictions to actually design drugs that are safe enough to test in people.
Max Jaderberg, the company's president, described the pipeline as both broad and exciting, though he didn't share specifics about which diseases they're targeting or how many drugs are in development.
For anyone watching the AI space, this marks a shift from AI as a research tool to AI as a drug creator. The timeline from founding to human trials has been remarkably fast compared to traditional pharma.
The real test comes next. Human trials will show whether AI-designed molecules work as well in bodies as they do in simulations. If they do, we could see a wave of new treatments developed faster and cheaper than ever before.
Isomorphic spun out of DeepMind in 2021, leveraging the AlphaFold protein-folding breakthrough. Now they're proving that understanding protein structures can translate into actual therapeutics, not just academic papers.
